We have now received the three attached reports on your study. As you will see, all referees find the story of interest and in principle suitable for publication in EMBO reports. Nevertheless, they also raise a number of issues with the strength and interpretation of the data, and addressing them would undoubtedly make for a stronger study.
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We have now received the three attached reports on your study. As you will see, all referees find the story of interest and in principle suitable for publication in EMBO reports. Nevertheless, they also raise a number of issues with the strength and interpretation of the data, and addressing them would undoubtedly make for a stronger study.
In essence, we feel all points raised are valid and should be addressed to the best of you ability. And the technical controls requested should definitely be provided. However, we also note the time pressure in this case and I would welcome your feedback on what you think you could do, within a relatively short time frame (of up to a maximum of 8 weeks) to respond to them.
When submitting your revised manuscript, please also include editable TIFF or EPS-formatted figure files, a separate PDF file of any Supplementary information (in its final format) and a letter detailing your responses to the referees. Revised manuscript should be approximately 30,000 characters long (including spaces). Please note that basic Materials and Methods required for understanding the experiments performed must remain in the main text, although additional detailed information may be included as Supplementary Material.
We now encourage the publication of original source data -particularly for electrophoretic gels and blots, but also for graphs-with the aim of making primary data more accessible and transparent to the reader. If you agree, you would need to provide one PDF file per figure that contains the original, uncropped and unprocessed scans of all or key gels used in the figures and an Excel sheet or similar with the data behind the graphs. The files should be labeled with the appropriate figure/panel number, and the gels should have molecular weight markers; further annotation could be useful but is not essential. The source files will be published online with the article as supplementary "Source Data" files and should be uploaded when you submit your final version. If you have any questions regarding this please contact me.
I look forward to your feedback on your plans for revision; maybe some of the requested experiments are already underway? I am currently in Japan (and will be in China next week) so I may be a little slow in responding, but time is of essence in this case and I will keep on top of the ball.
************ Note:
As part of the EMBO publication's Transparent Editorial Process, EMBO reports publishes online a Review Process File to accompany accepted manuscripts. This File will be published in conjunction with your paper and will include the referee reports, your point-by-point response and all pertinent correspondence relating to the manuscript.
You are able to opt out of this by letting the editorial office know (emboreports@embo.org). If you do opt out, the Review Process File link will point to the following statement: "No Review Process File is available with this article, as the authors have chosen not to make the review process public in this case." ************* REFEREE REPORTS:
The authors' group has studied Haspin, a mitotic kinase that phosphorylates Histone H3 Thr3 (H3T3ph), and have reported many important findings including the recruitment of CPC by direct interaction with H3T3ph at the centromere and positive feedback loop regulation between Haspin and Aurora B. In this manuscript, the authors report a new regulatory mechanism for Haspin in the synergistic phosphorylation by Cdk1 and Plk1. They found that Plk1 is required for the full activation of Haspin toward H3T3ph, and that the Cdk1-dependent phosphorylation of Haspin T128 leads to interaction between S-pT-P and Plk1-PBD. They further show that the Plk1-dependent phosphorylation of Haspin promotes its further activation. Based on these results, they conclude that the Cdk1-dependent Plk1-Haspin pathway is a new contributor to mitotic histone phosphorylation to achieve the full localization of CPC at centromeres.
The experiments are well designed and carefully performed, and the data are convincing in general. I recommend this manuscript for publication in EMBO reports if the concerns listed below are answered.
Comments: 1) Figure 2A The authors should check whether the phosphorylation band is observed in MBP-Haspin KD alone to confirm that MBP-Haspin KD has no kinase activity.
2) Figure 2B Does the phosphorylation of Haspin really depend on Cdk? Do MPM-2 signals disappear in myc-Haspin IP-ed prepared from Roscovitine-treated cells?
3) Figure 3B , C Is Haspin-7A phosphorylated at T128 and bind to Plk1-PBD? If so, the suggested model that Cdk1 phosphorylates Haspin and then Plk1 binds and phosphorylates Haspin can be accepted. Figure 4A , B Data in Fig4A and B are redundant. Fig4A would better be omitted. Figure 4D Plk1 inhibits the prophase cohesion removal pathway, which presumably affects the Haspin-CPC pathway. Therefore, that the authors should test the centromeric localization of Aurora B in Haspin-T128A or 7A-expressing cells as well. In addition, mitotic progression and chromosome segregation should be examined using Haspin-T128A and -7A mutants to clarify the biological significance of the Cdk1-Plk1-Haspin pathway.
4)

5)
6) Figure S2D Why doesn't the migration of Haspin change when the CDK1 activity is inhibited? 7) Figure S3 and 4 Scale bars are missing.
Referee #2 (Report):
In this paper, Higgins and colleagues investigate the role of Plk1 in the regulation of histone phosphorylation by the kinase Haspin. Haspin is an important kinase that phosphorylates Histone H3 at Thr3, which is necessary for normal recruitment of the Chromosomal Passenger Complex (CPC) to chromosomes/centromeres. Most of this work has been carried out by the same laboratory and represented landmark studies in our understanding of CPC regulation during mitosis. Now, the authors report based on solid and wellcontrolled biochemical experiments that Plk1 binds and phosphorylates Haspin upon Cdk1-mediated priming. This is reflected on the overall H3T3 phosphorylation levels and, as it would be predicted, in the proper recruitment of the catalytic CPC subunit Aurora B to centromeres. Overall, I think that this paper, although not a full story and falling slightly short regarding functional implications of Plk1-mediated phosphorylation of Haspin (e.g. impact on kinetochore-microtubule attachments and mitotic fidelity, etc), provides solid evidence for what is being claimed by the authors, which I believe will be of sufficient interest to the EMBO Rep. readership. I only have minor issues regarding some apparently conflicting results that I would like the authors to clarify.
Specific points: 1-The authors start their rationale highlighting the importance of Haspin in the regulation of CPC function. However, some of the results reported in this paper are not totally consistent with this model, neither they are consistent between different experiments. For instance, Histone H3 phosphorylation at S10, often used as read-out for Aurora B/CPC activity on chromosomes, appears not to be affected by Plk1 inhibition ( Figure 1A ), which should impair Haspin phosphorylation and consequently affect H3T3 phosphorylation and CPC localization/function. I would therefore expect some level of CPC activity to be downregulated, which is actually apparent in other figures in the paper (e.g. Figs. S1A and S1B, for Plk1 inhibition and Plk1 RNAi, respectively). What is the reason for this inconsistency between experiments and where does the "truth" stand? This should be clarified. Figure 1B , while H3T3 phosphorylation is almost absent in prophase cells treated with BI2536, there is still some H3T3 phosphorylation in prometaphase, but the reference for control cells in prometaphase is also much higher than in prophase. I guess that what I am asking is for a quantification for the real decrease in H3T3-ph fluorescence, in prophase vs. prometaphase cells. Figure 3B , the migration of the myc-Haspin T128A construct in mitosis is still much higher than myc-Haspin in interphase, suggesting that other phosphorylations in other residues are taking place that might be important for Haspin regulation during mitosis. How does the migration of the T128A mutant compare with Plk1 and/or Cdk1 inhibition during mitosis?
3-On
4-The authors refer to MPM2 as a Cdk1 generated epitope, but there is also evidence in the literature that Plk1/Polo is also able to generate this epitope (e.g. see Logarinho and Sunkel, 1998) . This should be taken into account in the interpretation of the results derived from this experiment.
5-The authors should discuss about the epistasis of CPC regulation by Plk1 and take that into account in their model, as there is also evidence in the literature supporting the regulation of Plk1 by the CPC (Carmena et al., 2012) .
Several recent studies have highlighted the importance of mitotic kinase crosstalk and feedback mechanism in the execution of cell division.
The manuscript by the Higgins lab describes a new connection in mitotic kinase signaling involving Cdk1-Plk1-Haspin-Aurora B. The work provides strong evidence that Plk1 activity is important for Haspin-driven phosphorylation of histine H3 at thr3 especially during early mitosis. A series of largely well controlled biochemical experiments suggest that Cdk1 primes Haspin for subsequent binding by Plk1, which could then phosphorylate Haspin to achieve the first wave of activation as cells enter mitosis. The manuscript is well written and will be of interest to researchers in the field of mitotic kinase signalling and cell division. In the opinion of this reviewer, the work is in principle suitable for publication in EMBO Reports.
Besides a few minor points (see below), this reviewer would suggest that the authors test their hypothesis (the Cdk1-Plk1-Haspin axis) in a more rigorous experiment by testing whether chemical inhibition of Plk1 or its depletion by RNAi shows a synergistic effect with Haspin-T128A allele or not. If the main function of Plk1 in contributing to H3 phosphorylation is via docking to Haspin on the PBD recognition site T128, there should be no or only minimally enhancement of the effects. This experiment could strengthen the main conclusion of the paper.
Minor points: -throughout the MS the authors refer to changes in electrophoretic mobility of proteins by the term "size"; I would suggest changing that to e.g. mobility in gels (or apparent molecular weight) -the experiment in Figure S1A should be performed by isolating mitotic cells after the 3hr exposure to compounds by shake off. As performed, the inhibition of Plk1 may have effects on protein phosphorylation by slowing down mitotic entry (a well established effect of Plk1 inhibition).
-The phosphorylation assay of Haspin by Cdk1-Cyclin B in Figure 2A is not very convincing. Have the authors got data corroborating the dependence of the radioactive Haspin label on active Cdk1 in this assay? -The data in Figure 4A would benefit from quantification using fluorescently labelled antibodies.
Correspondence -authors 24 October 2013
Thank you for your e-mail regarding our paper, EMBOR-2013-38080V1. We are very pleased that the referees found it interesting and acceptable in principle, and we are also very grateful to you and the referees for the speedy reviews.
We can certainly address the technical comments quite quickly. Some of the controls and supportive experiments (eg for the in vitro kinase assay) are already done, or we already have preliminary experiments that just need to be repeated to be sure that they are reproducible.
We will also try to carry out some of the suggested experiments that extend the manuscript by testing further phenotypes of the Haspin mutants. However, our previous experience tells us that we may encounter technical problems that make these experiments difficult. Specifically, we know that controlling Haspin expression level sufficiently to determine the effects of mutants on Aurora B localization is challenging, because both depletion and overexpression of wild type Haspin disrupts Aurora B localization (see Wang et al. Science 2010; 330:231-235 and Curr. Biol. 2011; 21:1061) . Nevertheless, we will give these experiments serious attention.
In summary, we have no doubt that we can resubmit within 8 weeks. However, we will aim for resubmission in around 4 weeks. By that time we will should have the key experiments done, and will know if further experiments with Haspin mutants have been or are likely to be successful.
We hope that this is reasonable, and please let us know if you have any questions.
Correspondence -editor 24 October 2013
These plans sound very reasonable indeed. I look forward to hearing from you and wish you success with the mutant Haspin experiments. They would be informative if feasible, and support the biological significance of the Cdk1-Plk1-Haspin pathway, but we will not insist if they turn out to be technically problematic. Referee #1 (Report):
Comments: 1) Figure 2A The authors should check whether the phosphorylation band is observed in MBP-Haspin KD alone to confirm that MBP-Haspin KD has no kinase activity. Figure 2A .
2) Figure 2B Does the phosphorylation of Haspin really depend on Cdk? Do MPM-2 signals disappear in myc-Haspin IP-ed prepared from Roscovitine-treated cells? Figure S2B . Also please see discussion of point 6 below.
MPM-2 signals do decrease sharply when myc-Haspin is immunoprecipitated from Roscovitine-treated cells, as now shown in
3) Figure 3B , C Is Haspin-7A phosphorylated at T128 and bind to Plk1-PBD? If so, the suggested model that Cdk1 phosphorylates Haspin and then Plk1 binds and phosphorylates Haspin can be accepted. Figure S3D . Figure 4A , B Data in Fig4A and B are redundant. Fig4A would better be omitted. Figure S6 . Figure 4D Plk1 inhibits the prophase cohesion removal pathway, which presumably affects the Haspin-CPC pathway. Therefore, that the authors should test the centromeric localization of Aurora B in Haspin-T128A or 7A-expressing cells as well. In addition, mitotic progression and chromosome segregation should be examined using Haspin-T128A and -7A mutants to clarify the biological significance of the Cdk1-Plk1-Haspin pathway. Figure S2D Why doesn't the migration of Haspin change when the CDK1 activity is inhibited? Figure S2D, Figure S2B ) consistent with the idea that phosphorylation of Haspin depends on Cdk activity. Figure S3 and 4 Scale bars are missing.
This is a good supporting experiment for our model that we have now carried out. The Haspin 7A mutations have no apparent effect on the phosphorylation of Haspin at T128 as detected by the anti-SpTP motif antibody. Furthermore, Haspin-7A also binds like wild type to GST-Plk1 PBD in a pulldown assay. This is now shown in
4)
While we realize that there is redundancy in these figures, we think that the quality of the Haspin blot in Fig 4A is better than in Fig 4B, and so we would prefer to keep both parts to clearly demonstrate the central finding that the T128A mutation reduces Haspin activity as measured by H3T3ph in cells. Moreover, we would like to show the H3T3ph blots of cells without doxycycline induction here, since similar experimental conditions were used in experiments for
5)
As requested, we have now assessed the centromeric localization of Aurora B in Haspindepleted cells transfected with Haspin WT and the T128A mutant (Fig S6
There is an inherent problem in determining the effect of Cdk inhibition on direct Cdk1 substrates in cells. This is because Cdk inhibition drives cells out of mitosis, and therefore could have quite indirect effects on protein phosphorylation. This is why we rely strongly on cell extract and in vitro analysis to make conclusions about phosphorylation of Haspin by Cdk1. When carrying out assays in mitotic cells with Cdk inhibitors (eg
7)
These have been added.
Specific points: 1-The authors start their rationale highlighting the importance of Haspin in the regulation of CPC function. However, some of the results reported in this paper are not totally consistent with this model, neither they are consistent between different experiments. For instance, Histone H3 phosphorylation at S10, often used as read-out for Aurora B/CPC activity on chromosomes, appears not to be affected by Plk1 inhibition ( Figure 1A ), which should impair Haspin phosphorylation and consequently affect H3T3 phosphorylation and CPC localization/function. I would therefore expect some level of CPC activity to be downregulated, which is actually apparent in other figures in the paper (e.g. Figs. S1A and S1B, for Plk1 inhibition and Plk1 RNAi, respectively). What is the reason for this inconsistency between experiments and where does the "truth" stand? This should be clarified.
In multiple published experiments, using either Haspin RNAi or Haspin inhibitors, we have not found a significant effect on H3S10ph in cells progressing through mitosis or arrested in mitosis (Wang et al. Science 2010; Curr Biol 2011; JCB 2012) . This is also clear from the results in Figure 1D . Figure 1A, 3F, S3A ). In contrast, as noted by the reviewer, and discussed in the first Results section, Plk1 inhibition ( Figure 1D and S1A) or Plk1 RNAi ( Figure S1B ) in cells entering mitosis does moderately reduce H3S10ph. As we stated in the original manuscript " this is unlikely to be an H3T3ph-mediated effect on Aurora B because direct inhibition of Haspin did not cause the same result ( Figure 1D ) and it could be due to phosphorylation of the CPC by Plk1". An alternative possibility is that the known role of Plk1 in mitotic entry indirectly reduces H3S10ph, but MPM2 and Cyclin B controls in Figure S1A and the immunofluorescence microscopy of mitotic cells in Figure 1C ,
D strongly argue against this idea. In short, differences in the role of Plk1 in initiating Aurora B activity towards H3S10ph versus its role in sustaining Aurora B activity towards H3S10ph may underlie the small differences observed. While the observation is not fully explained, it appears to be independent of Haspin activity, and we certainly do not consider it inconsistent with the model that Plk1 regulates Haspin.
2-The arguments that Plk1 activity is particularly relevant for Haspin phosphorylation in prophase are not particularly strong, especially because it is unclear against what the authors are comparing with (Prometaphase? Metaphase? Nocodazole-treated?). For instance, on Figure 1B , while H3T3 phosphorylation is almost absent in prophase cells treated with BI2536, there is still some H3T3 phosphorylation in prometaphase, but the reference for control cells in prometaphase is also much higher than in prophase. I guess that what I am asking is for a quantification for the real decrease in H3T3-ph fluorescence, in prophase vs. prometaphase cells.
We believe that Figure 1D already Figure S1C) . We hope that this figure makes clear that Plk1 inhibitors have the strongest relative effect in early mitosis, while Aurora B inhibitors have the strongest effect later in prometaphase. Figure 3B , the migration of the myc-Haspin T128A construct in mitosis is still much higher than myc-Haspin in interphase, suggesting that other phosphorylations in other residues are taking place that might be important for Haspin regulation during mitosis. How does the migration of the T128A mutant compare with Plk1 and/or Cdk1 inhibition during mitosis? 4-The authors refer to MPM2 as a Cdk1 generated epitope, but there is also evidence in the literature that Plk1/Polo is also able to generate this epitope (e.g. see Logarinho and Sunkel, 1998 5-The authors should discuss about the epistasis of CPC regulation by Plk1 and take that into account in their model, as there is also evidence in the literature supporting the regulation of Plk1 by the CPC (Carmena et al., 2012) .
3-On
We have now included mention of this possibility in the manuscript (page 6).
Referee #3 (Report):
Besides a few minor points (see below), this reviewer would suggest that the authors test their hypothesis (the Cdk1-Plk1-Haspin axis) in a more rigorous experiment by testing whether chemical inhibition of Plk1 or its depletion by RNAi shows a synergistic effect with Haspin-T128A allele or not. If the main function of Plk1 in contributing to H3 phosphorylation is via docking to Haspin on the PBD recognition site T128, there should be no or only minimally enhancement of the effects. This experiment could strengthen the main conclusion of the paper. Minor points: -throughout the MS the authors refer to changes in electrophoretic mobility of proteins by the term "size"; I would suggest changing that to e.g. mobility in gels (or apparent molecular weight)
We have altered this as requested.
-the experiment in Figure S1A should be performed by isolating mitotic cells after the 3hr exposure to compounds by shake off. As performed, the inhibition of Plk1 may have effects on protein phosphorylation by slowing down mitotic entry (a well established effect of Plk1 inhibition).
This was how the experiment was done, but it was not described adequately in the legend. This has now been corrected. Note that preexisting mitotic cells were removed by shake off prior to the experiment, and then cells for lysis were also collected by shake off at the end of the experiment.
-The phosphorylation assay of Haspin by Cdk1-Cyclin B in Figure 2A is not very convincing. Have the authors got data corroborating the dependence of the radioactive Haspin label on active Cdk1 in this assay?
We have now added an additional control. See reply to Reviewer 1, point 1. It should also be noted that we used kinase-deficient Haspin in this assay.
-The data in Figure 4A would benefit from quantification using fluorescently labelled antibodies. Thank you for the submission of your revised manuscript to EMBO reports. It was seen by referees 1 and 2, both of whom now support publication of your study and have no further comments. I am therefore happy to write with an 'accept in principle' decision, which means that I will be happy to accept your manuscript for publication once a few minor issues/corrections have been addressed, as follows.
-I have noted that the material and methods section of the main text is very succinct. Please note that basic Materials and Methods required for understanding the experiments performed must remain in the main text, although additional detailed information necessary to reproduce them may be included as Supplementary Material.
